Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on May 7, 2014, reporting events occurring on May 2, 2014. The filing details a material definitive agreement involving the amendment of an existing office lease and the addition of new leased space in Redwood City, California.
Key Financial Metrics and Obligations
The filing does not provide revenue, profit, cash flow, or margin data. The primary financial disclosure relates to a new direct financial obligation:
- Total Remaining Base Rent Obligation: Approximately $2.7 million as of May 2, 2014.
- Current Premises: 13,787 square feet with an extended term expiring January 31, 2018.
- Expansion Space: 12,106 square feet with a 42-month term commencing August 1, 2014.
- Additional Costs: The Company is responsible for specified percentages of operating expenses and taxes.
Rent Schedule Details
| Property | Period | Monthly Base Rent |
|---|---|---|
| Current Premises | May 9, 2016 to May 8, 2017 | $35,961.55 |
| Current Premises | May 9, 2017 to Jan 31, 2018 | $37,040.40 |
| Expansion Space | Months 1-12 | $23,001.40 |
| Expansion Space | Months 13-24 | $23,691.44 |
| Expansion Space | Months 25-36 | $24,402.18 |
| Expansion Space | Months 37-42 | $25,134.25 |
Material Changes and Outlook
The material change is the extension of the existing lease term by 20 months and 22 days and the addition of 12,106 square feet of adjacent office space. The Company holds an option to extend the lease for an additional five years at a market rate determined according to the Existing Lease terms. The filing does not contain management commentary on financial outlook, risks, or contingencies beyond the lease obligations.
Investor Verification Checklist
- Verify the total remaining base rent obligation of approximately $2.7 million against the company's current cash position.
- Confirm the commencement date of the Expansion Space rent payments (August 1, 2014).
- Review the full text of the First Amendment to Lease (Exhibit 10.1) for details on operating expense percentages and termination clauses.
- Assess the impact of the increased fixed costs on the company's burn rate given the lack of revenue data in this filing.